A.I. allows 'dynamic dosing' for cancer drugs - Futurity

You are free to share this article under the Attribution 4.0 International license. Researchers have harnessed a powerful artificial intelligence platform to successfully treat a patient with advanced cancer, completely halting disease progression. The development represents a big step forward in personalized medicine, they say. In this clinical study, researchers gave a patient with metastatic castration-resistant prostate cancer (MCRPC) a novel drug combination consisting of the investigational drug ZEN-3694 and enzalutamide, an approved prostate cancer drug. The research team successfully used the platform, called CURATE.AI, to continuously identify the optimal doses of each drug to result in a durable response, allowing the patient to resume a completely normal and active lifestyle.